Webnewsroom - press release. Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOxTM System for Chronic Bronchitis. First-of-its-kind RheOx device designed to reduce mucus-producing cells and improve quality of life. Menlo Park, CA Sept. 4, 2024 – Gala Therapeutics, Inc. (Gala) today announced that its RheOx TM system has received ... WebGala Therapeutics 1,764 followers on LinkedIn. Gala Therapeutics Gala Therapeutics is a privately-held medical device company based in Menlo Park, CA that was formed by Apple Tree Partners ...
Gala Therapeutics begins RheOx bronchial rheoplasty system trial
WebMay 20, 2024 · SAN CARLOS, Calif., May 20, 2024 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx™ Bronchial Rheoplasty System for the treatment of the symptoms of chronic bronchitis. The first patient procedures in the RheSolve clinical trial … WebFeb 23, 2024 · US-based medical device company Gala Therapeutics is set to begin its pivotal RheSolve clinical trial to evaluate the RheOx Bronchial Rheoplasty System for … people\\u0027s health gcse
RheOx for Chronic Bronchitis
WebMobile eTicket. The Resolution Project is excited to invite you to our 11th Annual Gala, Resolve 2024! Join us as we celebrate our global network of more than 600 Resolution Fellows representing over 360 social ventures in over 80 countries, who have helped over 6 million people. Early Bird ticket prices last until April 17th! WebGala Therapeutics’ RheOx TM System Showcased in Live Case at Virtual European Respiratory Society (ERS) Congress as Part of Post-Market Chronic Bronchitis Study. … WebGala Media. 576 likes · 4 talking about this. GALA MEDIA FILMS PRODUCTIONS Videos Worth Watching Welcome to Gala Media Films Productions. We make to know who he is is to be where he was